5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist - PubMed (original) (raw)

5-HT3 receptor antagonism by anpirtoline, a mixed 5-HT1 receptor agonist/5-HT3 receptor antagonist

M Göthert et al. Br J Pharmacol. 1995 Jan.

Abstract

1. The aim of this study was to provide evidence that anpirtoline, which is an agonist at 5-HT1B and 5-HT1D receptors and also displays submicromolar affinity for 5-HT1A recognition sites, in addition, acts as an antagonist at 5-HT3 receptors. 2. In radioligand binding studies on rat brain cortical membranes, anpirtoline inhibited specific binding of [3H]-(S)-zacopride to 5-HT3 receptor recognition sites (pKi: 7.53). 3. In N1E-115 neuroblastoma cells in which [14C]-guanidinium was used as a tool to measure cation influx through the 5-HT3 receptor channel, the 5-HT-induced influx was concentration-dependently inhibited by anpirtoline. In this respect, anpirtoline mimicked other 5-HT3 receptor antagonists; the rank order of potency was ondansetron > anpirtoline > metoclopramide. 4. The concentration-response curve for 5-HT as a stimulator of [14C]-guanidinium influx was shifted to the right by anpirtoline (apparent pA2: 7.78). 5. In urethane-anaesthetized rats, anpirtoline inhibited (at lower potency than zacopride and tropisetron) the 5-HT- or phenylbiguanide-induced bradycardia (Bezold-Jarisch reflex), but did not induce this reflex by itself. 6. Intravenous infusion of cisplatin in the domestic pig caused a consistent emetic response which was antagonized by anpirtoline. 7. It is concluded that anpirtoline, which was previously characterized as a 5-HT1 receptor agonist also proved to be a 5-HT3 receptor antagonist in several experimental models and, hence, exhibits a unique pattern of properties at different 5-HT receptors.

PubMed Disclaimer

Similar articles

• SR 57227A: a potent and selective agonist at central and peripheral 5-HT3 receptors in vitro and in vivo.
  Bachy A, Héaulme M, Giudice A, Michaud JC, Lefevre IA, Souilhac J, Manara L, Emerit MB, Gozlan H, Hamon M, et al. Bachy A, et al. Eur J Pharmacol. 1993 Jun 24;237(2-3):299-309. doi: 10.1016/0014-2999(93)90282-m. Eur J Pharmacol. 1993. PMID: 7689975
• RS 23597-190: a potent and selective 5-HT4 receptor antagonist.
  Eglen RM, Bley K, Bonhaus DW, Clark RD, Hegde SS, Johnson LG, Leung E, Wong EH. Eglen RM, et al. Br J Pharmacol. 1993 Sep;110(1):119-26. doi: 10.1111/j.1476-5381.1993.tb13780.x. Br J Pharmacol. 1993. PMID: 8220871 Free PMC article.
• Anpirtoline, a novel, highly potent 5-HT1B receptor agonist with antinociceptive/antidepressant-like actions in rodents.
  Schlicker E, Werner U, Hamon M, Gozlan H, Nickel B, Szelenyi I, Göthert M. Schlicker E, et al. Br J Pharmacol. 1992 Mar;105(3):732-8. doi: 10.1111/j.1476-5381.1992.tb09047.x. Br J Pharmacol. 1992. PMID: 1628159 Free PMC article.
• Selectivity of 5-HT3 receptor antagonists and anti-emetic mechanisms of action.
  Freeman AJ, Cunningham KT, Tyers MB. Freeman AJ, et al. Anticancer Drugs. 1992 Apr;3(2):79-85. Anticancer Drugs. 1992. PMID: 1525396 Review.
• Desperately seeking subunits: are native 5-HT3 receptors really homomeric complexes?
  Fletcher S, Barnes NM. Fletcher S, et al. Trends Pharmacol Sci. 1998 Jun;19(6):212-5. doi: 10.1016/s0165-6147(98)01210-3. Trends Pharmacol Sci. 1998. PMID: 9666711 Review.

Cited by

• Serotonin and beyond-a tribute to Manfred Göthert (1939-2019).
  Bönisch H, Fink KB, Malinowska B, Molderings GJ, Schlicker E. Bönisch H, et al. Naunyn Schmiedebergs Arch Pharmacol. 2021 Sep;394(9):1829-1867. doi: 10.1007/s00210-021-02083-5. Epub 2021 May 15. Naunyn Schmiedebergs Arch Pharmacol. 2021. PMID: 33991216 Free PMC article. Review.
• Local potentiation of excitatory synapses by serotonin and its alteration in rodent models of depression.
  Cai X, Kallarackal AJ, Kvarta MD, Goluskin S, Gaylor K, Bailey AM, Lee HK, Huganir RL, Thompson SM. Cai X, et al. Nat Neurosci. 2013 Apr;16(4):464-72. doi: 10.1038/nn.3355. Epub 2013 Mar 17. Nat Neurosci. 2013. PMID: 23502536 Free PMC article.
• Chronic reductions in serotonin transporter function prevent 5-HT1B-induced behavioral effects in mice.
  Shanahan NA, Holick Pierz KA, Masten VL, Waeber C, Ansorge M, Gingrich JA, Geyer MA, Hen R, Dulawa SC. Shanahan NA, et al. Biol Psychiatry. 2009 Mar 1;65(5):401-8. doi: 10.1016/j.biopsych.2008.09.026. Epub 2008 Nov 14. Biol Psychiatry. 2009. PMID: 19013555 Free PMC article.
• Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites.
  Molderings GJ, Schmidt K, Bönisch H, Göthert M. Molderings GJ, et al. Naunyn Schmiedebergs Arch Pharmacol. 1996 Aug-Sep;354(3):245-52. doi: 10.1007/BF00171054. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8878053

References

1. 1. Br J Pharmacol. 1993 Feb;108(2):436-42 - PubMed
2. 1. J Pharmacol Exp Ther. 1992 Dec;263(3):1015-22 - PubMed
3. 1. J Neurochem. 1993 Jun;60(6):2059-67 - PubMed
4. 1. J Biol Chem. 1951 Nov;193(1):265-75 - PubMed
5. 1. Proc Natl Acad Sci U S A. 1972 Jan;69(1):258-63 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Medical

  • MedlinePlus Health Information